MedTrace Logo

Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Bronchiolitis.

NCT01276821 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-05-31

Study results available
· View outcomes & findings →

Summary

To assess the efficacy of nebulized 3% hypertonic saline in improving clinical severity scores among children aged 6 weeks to 24 months with bronchiolitis.

Conditions

  • Bronchiolitis

Interventions

DRUG

L-Epinephrine and Normal Saline (0.9%)

1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline

DRUG

L-Epinephrine and Hypertonic Saline (3%)

1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline

Sponsors & Collaborators

  • Dr. Aayush Khanal, MD

    lead OTHER

Principal Investigators

  • Aayush Khanal, MD · Department of Child Health , Institute of Medicine , Tribhuvan University Teaching Hospital.

  • Arun Sharma, MD · Department of Child Health , Tribhuvan University Teaching Hospital , Institute of Medicine, Maharajgunj, Kathmandu ,Nepal.

  • Srijana Basnet, MD · Department of Child Health , Tribhuvan University Teaching Hospital , Institute of Medicine , Maharajgunj , Kathmandu , Nepal.

  • Pushpa R Sharma, DCH,FCPS · Head of the Department. Department of Child Health , Tribhuvan University Teaching Hospital , Institute of Medicine , Maharajgunj , Kathmandu , Nepal.

  • Fakir C Gami, MD · Department of Child Health, Tribhuvan University Teaching Hospital, Institute of Medicine.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Weeks
Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Nepal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01276821 on ClinicalTrials.gov